The global cardiac biomarkers market size was estimated at USD 4.7 billion in 2015. Rising prevalence of cardiovascular diseases globally and escalating popularity of POC testing are some of the main factors contributing toward the market growth. Cardiac biomarkers are the substances released in the bloodstream due to heart related damage and stress. as a result of insufficient blood supply to the heart. The detection of the biomarkers is used for the identification of various heart conditions such as, acute coronary syndrome, acute myocardial infarction, ischemia, congestive heart failure.
High prevalence of cardiovascular diseases worldwide has resulted into a significant growth in the cardiac biomarkers market. According to the WHO, about 17.5 million people globally suffer from some heart condition. The increasing preference to the use of the cardiac kits and more awareness among the people regarding the application of the cardiac biomarkers is expected to augment the market in the near future.
Download Free Sample - https://www.millioninsights.com/industry-reports/cardiac-biomarker-market/request-sample
Type Insights
Based on the types, the cardiac biomarker market is classified into the troponin, creatinine- kinase MB, Natriuretic peptides- b-type Natriuretic peptide and N terminal pro b–type Natriuretic peptide, myoglobin, and others. Troponin tests are in large demand for the detection of the AMI with efficient diagnosis of cardiovascular disorders. This growing demand has resulted in tremendous market growth of this segment.
Natriuretic peptides held the second largest share in 2015. The increasing incidence of the cardiovascular disorders has led to the surge in demand of these products, further attributing to the growth of the segment.
Application Insights
Based on application, the market is segmented into ACS (acute coronary syndrome), AMI (acute myocardial infarction), and CHF (congestive heart failure). The cardiac biomarkers have major application in the diagnosis of ACS and thus, this segment accounted for largest revenue generating sector. According to American Heart Association (AHA), the Americans are estimated to spend around USD 150 billion for treating ACS posing a huge social and economic burden.
Followed by ACS, myocardial infarction held the second largest market share in 2015. The increasing number of the geriatric population has led to the growth of the sector, in this segment, as the elderly population is more prone to cardiac-related ailments. In addition, the growing unhealthy, sedentary lifestyle and alcohol consumption has further augmented the chances of the heart problems, hence, boosting the cardiac biomarker market growth.
End User Insights
The end user segment is fragmented into two types namely, laboratory testing and point of testing (PoC). The laboratory testing held the largest revenue share in 2015. Increasing incidence and prevalence of heart-related diseases is expected to flourish the segment growth.
The PoC testing segment is projected to witness growth at the highest CAGR during the forecast period. The rising demand for the PoC segment has led to the growth of the segment. Moreover, the rising awareness in the developing countries regarding the use of PoC testing and its application in cardiac biomarkers has nurtured the market growth.
Comments
Post a Comment